Jeffrey Chodakewitz

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) tumbled by more than 6 percent on Friday after the company confirmed it has received a letter from the U.S. Food and Drug Administration for use of Kalydeco in people with cystic fibrosis. Vertex Pharmaceuticals said that it received...

Early Tuesday morning, Vertex Pharmaceuticals (NASDAQ: VRTX) issued a press release announcing that its two phase 3 studies of Lumacaftor in combination with ivacaftor met the primary endpoint with "statistically significant improvement in lung function." Shares of Vertex have...